8AK logo

Alkermes DB:8AK Stock Report

Last Price

€30.40

Market Cap

€4.9b

7D

1.3%

1Y

24.6%

Updated

02 Feb, 2025

Data

Company Financials +

Alkermes plc

DB:8AK Stock Report

Market Cap: €4.9b

8AK Stock Overview

A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. More details

8AK fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 61.3% below our estimate of its fair value

Risk Analysis

Earnings are forecast to decline by an average of 10.7% per year for the next 3 years


My Notes

Capture your thoughts, links and company narrative

Alkermes plc Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€946.4m

SCHOTT Pharma KGaA

XTRA:1SXP

€3.6b

Gerresheimer

XTRA:GXI

€2.3b

Price History & Performance

Summary of share price highs, lows and changes for Alkermes
Historical stock prices
Current Share PriceUS$30.40
52 Week HighUS$30.40
52 Week LowUS$20.80
Beta0.46
1 Month Change10.14%
3 Month Change26.67%
1 Year Change24.59%
3 Year Change46.15%
5 Year Change64.32%
Change since IPO184.64%

Recent News & Updates

Recent updates

Shareholder Returns

8AKDE BiotechsDE Market
7D1.3%1.0%1.9%
1Y24.6%-4.3%15.1%

Return vs Industry: 8AK exceeded the German Biotechs industry which returned -4.3% over the past year.

Return vs Market: 8AK exceeded the German Market which returned 15.1% over the past year.

Price Volatility

Is 8AK's price volatile compared to industry and market?
8AK volatility
8AK Average Weekly Movement4.8%
Biotechs Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 8AK has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 8AK's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19872,100Richard Popswww.alkermes.com

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.

Alkermes plc Fundamentals Summary

How do Alkermes's earnings and revenue compare to its market cap?
8AK fundamental statistics
Market cap€4.92b
Earnings (TTM)€373.29m
Revenue (TTM)€1.45b

13.2x

P/E Ratio

3.4x

P/S Ratio

Is 8AK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8AK income statement (TTM)
RevenueUS$1.51b
Cost of RevenueUS$253.34m
Gross ProfitUS$1.25b
Other ExpensesUS$864.83m
EarningsUS$386.95m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.39
Gross Margin83.17%
Net Profit Margin25.71%
Debt/Equity Ratio22.4%

How did 8AK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 07:30
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alkermes plc is covered by 36 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Robert HazlettBMO Capital Markets U.S. (Historical)
Jason Matthew GerberryBofA Global Research